Summary & Overview
HCPCS J9261: Injection, nelarabine, 50 mg
HCPCS Level II code J9261 denotes a 50 mg unit of nelarabine for injection, a chemotherapeutic agent used in oncology treatment regimens. Nationally, accurate coding of antineoplastic agents matters for clinical documentation, billing consistency, and oversight of high-cost drug use. This code captures drug supply units rather than the administration procedure itself, which affects reimbursement workflows and claim line reporting. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for nelarabine, common sites of service where the drug is administered, and the implications of using a HCPCS Level II J-code for unit-based chemotherapy billing. The publication summarizes benchmark considerations for unit reporting, typical payer coverage patterns, and where to locate relevant policy guidance. It also outlines what to expect in claim construction when a high-cost injectable oncology drug is billed using a J-code, and directs readers to payer-specific rules and national Medicare payment policies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9261 represents Injection, nelarabine, 50 mg. This code is used to report administration of nelarabine, a chemotherapy agent, supplied in 50 mg units for intravenous injection.
-
Service type: Chemotherapy drug administration
-
Typical site of service: Hospital outpatient department, oncology infusion center, or clinic providing parenteral chemotherapy
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma who is scheduled to receive systemic nelarabine chemotherapy. The patient presents to an outpatient oncology infusion center or an inpatient hematology/oncology unit for administration. Pre-infusion workflow includes verification of diagnosis and prior therapies, baseline neurologic assessment, review of prior laboratory results (complete blood count, metabolic panel), confirmation of venous access (peripheral IV or central venous catheter), medication order verification by pharmacy, and chemotherapy consent documentation. Nelarabine is prepared by pharmacy as a preservative-free injectable solution and dosed per body surface area; J9261 denotes each 50 mg unit of the drug for billing. During infusion, nursing monitors for infusion-related reactions, neurotoxicity signs, and cytopenia-related complications. Post-infusion care includes observation for acute adverse events, scheduling of subsequent cycles, documentation of drug lot and units administered, and coordination of supportive care (growth factor support, antiemetics, antimicrobial prophylaxis) as indicated. Typical sites of service are an outpatient hospital-based or freestanding infusion center, physician office infusion suite, or inpatient oncology ward depending on patient acuity and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |